Herantis Pharma Plc.
8
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
12.5%
1 terminated/withdrawn out of 8 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease
Role: lead
Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
Role: lead
Single Ascending Doses of HER-096 in Healthy Subjects
Role: lead
A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema
Role: lead
Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions
Role: collaborator
Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study
Role: lead
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
Role: lead
Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye
Role: lead
All 8 trials loaded